{"id":"tarceva-erlotinib-hcl","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Rash"},{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition prevents the activation of downstream signaling pathways that promote cell proliferation and survival, ultimately leading to the death of cancer cells. Erlotinib has been shown to be effective in treating non-small cell lung cancer, pancreatic cancer, and other types of cancer. The exact mechanism of action is complex and involves multiple molecular pathways.","oneSentence":"Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:36.266Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, pancreatic cancer, and other types of cancer"},{"name":"Locally advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00045201","phase":"PHASE1","title":"Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06-13","conditions":"Adult Solid Neoplasm","enrollment":60},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT01660971","phase":"PHASE1","title":"Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-30","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7","enrollment":19},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT00878163","phase":"PHASE1","title":"GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03-31","conditions":"Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":55},{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT02759614","phase":"PHASE3","title":"Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-04-01","conditions":"NSCLC","enrollment":311},{"nctId":"NCT01204372","phase":"PHASE2","title":"Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2010-06","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":63},{"nctId":"NCT01013649","phase":"PHASE3","title":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-05","conditions":"Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm","enrollment":546},{"nctId":"NCT07418177","phase":"PHASE1, PHASE2","title":"Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-10","conditions":"AMD - Age-Related Macular Degeneration","enrollment":9},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT07143045","phase":"","title":"A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases","status":"RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2025-12-29","conditions":"EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases","enrollment":800},{"nctId":"NCT02152631","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-10-03","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT06545695","phase":"PHASE1, PHASE2","title":"Epidermal Growth Factor Receptor Inhibition for Keratinopathies","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2027-07-01","conditions":"Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita","enrollment":44},{"nctId":"NCT06675695","phase":"","title":"Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-30","conditions":"Non Small Cell Lung Cancer","enrollment":4864},{"nctId":"NCT01897480","phase":"PHASE2","title":"A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":168},{"nctId":"NCT05827614","phase":"PHASE1","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2023-03-24","conditions":"Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma","enrollment":85},{"nctId":"NCT02411448","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2015-05-06","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":545},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT00596648","phase":"PHASE1, PHASE2","title":"A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Exelixis","startDate":"2008-02-12","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":92},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT01708954","phase":"PHASE2","title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-13","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7","enrollment":125},{"nctId":"NCT01927744","phase":"PHASE2","title":"Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-16","conditions":"Head and Neck Cancer","enrollment":55},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT04172779","phase":"PHASE2","title":"Erlotinib for Hepatocellular Carcinoma Chemoprevention","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Cirrhosis, Liver, Advanced Liver Fibrosis","enrollment":60},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT01186861","phase":"PHASE2","title":"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-04","conditions":"Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","enrollment":205},{"nctId":"NCT01221077","phase":"PHASE2","title":"Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-04-08","conditions":"NSCLC, Non Small Cell Lung Cancer","enrollment":88},{"nctId":"NCT00600496","phase":"PHASE1","title":"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2007-12-14","conditions":"Breast Cancer, Breast Neoplasms, Colon Cancer","enrollment":140},{"nctId":"NCT00977470","phase":"PHASE2","title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2009-10","conditions":"Non-small Cell Lung Cancer","enrollment":76},{"nctId":"NCT00885066","phase":"PHASE1","title":"Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2008-05","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT00954226","phase":"PHASE1","title":"Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-05","conditions":"Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma","enrollment":48},{"nctId":"NCT02099058","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2014-01-15","conditions":"Advanced Solid Tumors Cancer","enrollment":237},{"nctId":"NCT05442060","phase":"PHASE2","title":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"OBI Pharma, Inc","startDate":"2022-07-27","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT06161558","phase":"PHASE1","title":"Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-15","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT06997068","phase":"PHASE2","title":"Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-09","conditions":"Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8","enrollment":25},{"nctId":"NCT00076310","phase":"PHASE2","title":"OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01-28","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT07036016","phase":"","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2015-01-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":67818},{"nctId":"NCT01393821","phase":"NA","title":"Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-23","conditions":"Dermatologic Complications, Malignant Neoplasm, Pain","enrollment":27},{"nctId":"NCT02991651","phase":"PHASE1","title":"Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC","status":"TERMINATED","sponsor":"Io Therapeutics","startDate":"2016-12-07","conditions":"Lung Cancer, Nonsmall Cell","enrollment":12},{"nctId":"NCT00405405","phase":"PHASE1","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-12","conditions":"Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer","enrollment":13},{"nctId":"NCT01555489","phase":"PHASE2","title":"Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2011-10","conditions":"Stage IV Pancreatic Cancer","enrollment":11},{"nctId":"NCT00954525","phase":"PHASE1","title":"Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-07","conditions":"Metastatic Pancreatic Cancer","enrollment":14},{"nctId":"NCT00942734","phase":"PHASE2","title":"Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Head And Neck Cancer","enrollment":49},{"nctId":"NCT00640978","phase":"PHASE2","title":"Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-03","conditions":"Pancreatic Cancer","enrollment":16},{"nctId":"NCT00983307","phase":"PHASE2","title":"A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-08-27","conditions":"Carcinoma, Non-small-cell Lung","enrollment":17},{"nctId":"NCT05525858","phase":"","title":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-09-28","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Cancer","enrollment":1000},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT00448240","phase":"PHASE2, PHASE3","title":"Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2007-02","conditions":"Head and Neck Cancer, Carcinoma, Squamous Cell","enrollment":6},{"nctId":"NCT00503971","phase":"PHASE1, PHASE2","title":"Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.","status":"TERMINATED","sponsor":"Spanish Lung Cancer Group","startDate":"2008-05","conditions":"Non-small Cell Lung Cancer","enrollment":33},{"nctId":"NCT00446225","phase":"PHASE3","title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT02535338","phase":"PHASE1, PHASE2","title":"Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-11","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7","enrollment":11},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT01130519","phase":"PHASE2","title":"A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05-06","conditions":"HLRCC, Sporadic Papillary Renal Cell Cancer","enrollment":83},{"nctId":"NCT00708448","phase":"PHASE1","title":"Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2008-03-28","conditions":"Cancer, Non Small Cell Lung Cancer","enrollment":26},{"nctId":"NCT06516887","phase":"PHASE1, PHASE2","title":"Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-12-27","conditions":"Advanced Lung Adenocarcinoma","enrollment":44},{"nctId":"NCT06071013","phase":"PHASE1, PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation","enrollment":20},{"nctId":"NCT01032070","phase":"PHASE2","title":"Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma","status":"TERMINATED","sponsor":"OSI Pharmaceuticals","startDate":"2010-09-27","conditions":"Recurrent or Refractory Pediatric Ependymoma","enrollment":25},{"nctId":"NCT02588261","phase":"PHASE3","title":"A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":530},{"nctId":"NCT01247922","phase":"PHASE2","title":"Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205","status":"TERMINATED","sponsor":"OSI Pharmaceuticals","startDate":"2011-05-23","conditions":"Ependymoma","enrollment":4},{"nctId":"NCT02495233","phase":"PHASE1, PHASE2","title":"A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-09-08","conditions":"Non-Small-Cell Lung Cancer","enrollment":10},{"nctId":"NCT01010945","phase":"PHASE1","title":"Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"OSI Pharmaceuticals","startDate":"2010-02-03","conditions":"Advanced Pancreatic Cancer","enrollment":19},{"nctId":"NCT00739453","phase":"PHASE1","title":"A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-10-23","conditions":"Advanced Solid Tumors","enrollment":95},{"nctId":"NCT02057380","phase":"PHASE2","title":"A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-04-16","conditions":"Advanced Solid Tumors","enrollment":13},{"nctId":"NCT06678230","phase":"PHASE2","title":"Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2024-11","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT02364609","phase":"PHASE1","title":"Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib","status":"COMPLETED","sponsor":"Jonathan Riess","startDate":"2015-09-30","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer","enrollment":11},{"nctId":"NCT01306045","phase":"PHASE2","title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic","enrollment":647},{"nctId":"NCT00720304","phase":"PHASE2","title":"Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-11-19","conditions":"Head and Neck Cancer","enrollment":43},{"nctId":"NCT00881166","phase":"PHASE1","title":"Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2007-11","conditions":"Malignant Disease","enrollment":101},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT02091141","phase":"PHASE2","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2014-04-14","conditions":"Neoplasms, Solid Tumors, Biliary Cancer","enrollment":673},{"nctId":"NCT01064479","phase":"PHASE2","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-02-05","conditions":"Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity","enrollment":123},{"nctId":"NCT00254384","phase":"PHASE1","title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-10-05","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":50},{"nctId":"NCT03192501","phase":"","title":"iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2017-07-01","conditions":"Lung Cancer, Gene Abnormality, Gene Product Sequence Variation","enrollment":250},{"nctId":"NCT03076164","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-03-01","conditions":"Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic","enrollment":24},{"nctId":"NCT02273362","phase":"PHASE1, PHASE2","title":"Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-11-24","conditions":"Cirrhosis, Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":"Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma","enrollment":744},{"nctId":"NCT02098954","phase":"PHASE2","title":"Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-07-01","conditions":"Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation","enrollment":40},{"nctId":"NCT03647592","phase":"","title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-06-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT01116622","phase":"PHASE1","title":"Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-04","conditions":"Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)","enrollment":24},{"nctId":"NCT00590902","phase":"PHASE2","title":"Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-03","conditions":"Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer","enrollment":81},{"nctId":"NCT01174043","phase":"PHASE2","title":"Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Indiana University","startDate":"2010-07","conditions":"Leukemia, Myelomonocytic, Acute","enrollment":11},{"nctId":"NCT05081674","phase":"PHASE2","title":"Brazilian Lung Immunotherapy Study","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-01-01","conditions":"Lung Neoplasm","enrollment":154},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT00079053","phase":"PHASE1","title":"Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2004-03-02","conditions":"Head and Neck Cancer","enrollment":19},{"nctId":"NCT01068587","phase":"PHASE1, PHASE2","title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2010-01-21","conditions":"Lung Cancer","enrollment":31},{"nctId":"NCT05934461","phase":"","title":"A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Laibin People's Hospital","startDate":"2014-12-01","conditions":"The Primary Study Metric is Progression-free Survival (PFS)","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OSI-774"],"phase":"phase_3","status":"active","brandName":"Tarceva (erlotinib HCl)","genericName":"Tarceva (erlotinib HCl)","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, pancreatic cancer, and other types of cancer, Locally advanced or metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}